Literature DB >> 1650216

Selective inhibition of cGMP-inhibited and cGMP-noninhibited cyclic nucleotide phosphodiesterases and relaxation of rat aorta.

S Lindgren1, A Rascón, K E Andersson, V Manganiello, E Degerman.   

Abstract

In the supernatant (50,000 g, 1 hr) fraction from rat aortic smooth muscle homogenates, approximately 50% of total cAMPE PDE activity was inhibited by OPC 3911 (3 microM), while approximately 20% was inhibited by rolipram (30 microM). A cGMP-inhibited cyclic nucleotide phosphodiesterase (cGI-PDE) was further purified using DEAE chromatography followed by affinity chromatography on the N-(2-isothiocyanato)ethyl derivative of cilostamide conjugated to aminoethyl agarose (CIT-agarose). OPC 3911, CI-930, and milrinone, but not rolipram, were potent and selective inhibitors of this enzyme. The PDE-activity in the CIT-agarose flow through fraction (RI-PDE), however, was inhibited potently by rolipram, but not by cGMP, OPC 3911, CI-930 or milrinone. Functional studies showed that OPC 3911, CI-930, and milrinone were potent relaxants of contracted rat aorta. Rolipram had little relaxant effect. When OPC 3911 or milrinone was combined with rolipram more than additive effects on aortic relaxation and cAMP content were obtained. OPC 3911 combined with milrinone had only additive effects. These results demonstrate the presence of a cGI-PDE in rat aortic smooth muscle, and that inhibition of this isozyme may be of primary importance for the relaxant effects of OPC 3911, CI-930, and milrinone. A RI-PDE activity was also found, but it appeared to be less important for modulation of vascular tone unless the cGI-PDE was already inhibited. This may explain the synergistic relaxant effects observed when both PDE-isozymes were inhibited.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650216     DOI: 10.1016/0006-2952(91)90317-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype.

Authors:  S D Rybalkin; K E Bornfeldt; W K Sonnenburg; I G Rybalkina; K S Kwak; K Hanson; E G Krebs; J A Beavo
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

2.  Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase.

Authors:  J E Souness; L C Scott
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

3.  Effects of two vasodilatory phosphodiesterase inhibitors on bradykinin-induced permeability increase in the hamster cheek pouch.

Authors:  E Svensjö; K E Andersson; E Bouskela; F Z Cyrino; S Lindgren
Journal:  Agents Actions       Date:  1993-05

4.  Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.

Authors:  A E Eckly; C Lugnier
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

5.  Cytochemical distribution of cyclic AMP-dependent 3',5'-nucleotide phosphodiesterase in the rat myocardium.

Authors:  L Okruhlicová; N Tribulová; A Eckly; C Lugnier; J Slezák
Journal:  Histochem J       Date:  1996-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.